Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.06 -0.13 (-0.20%)
Streaming Delayed Price Updated: 9:39 AM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical... 
Via Benzinga
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
Conduit Pharmaceuticals has entered an exclusive licensing agreement with AstraZeneca to develop AZD1656, AZD5658, and AZD5904, targeting autoimmune disorders and idiopathic male infertility. Conduit... 
Via Benzinga
Top Analyst Reports For AstraZeneca, TotalEnergies & ConocoPhillips
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC, TotalEnergies SE and ConocoPhillips. 
Via Talk Markets
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
The winners of today might not compete in the lucrative new segment of tomorrow. 
Via The Motley Fool
Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2%
The Bank of England cuts interest rate for first time in over 4 years to 5%, citing inflation below target and emerging economic slack. Pound falls, UK stocks hold steady. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment
AstraZeneca CEO Pascal Soriot urges the UK government to reassess drug funding after NICE deems Enhertu too costly, highlighting concerns over new methodology affecting advanced cancer treatments and... 
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks arguably deserve more respect from investors. 
Via The Motley Fool
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu. 
Via MarketBeat
Topics ETFs
7 Explosive Growth Stocks Set to Soar in 2024
These seven explosive growth stocks across various sectors have the potential to deliver substantial returns for investors in 2024. 
Via InvestorPlace
Why AstraZeneca Stock Is Sliding Today
The British drugmaker's Q2 results were good, but seemingly not good enough for many investors. 
Via The Motley Fool
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
AZN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook
The company no longer expects its earnings to decline this year. Instead, AstraZeneca called for stable profit. 
Via Investor's Business Daily
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown. 
Via Benzinga
Topics Economy
Exposures Economy
AstraZeneca Posts Mixed Q2 Earnings, Still Raises Annual Guidance On Strong Demand For Cancer, Rare Disease Medicines
AstraZeneca's Q2 sales rose 13% to $12.94 billion, beating expectations. Oncology sales grew 15% to $5.33 billion. Notable drug performances include Tagrisso up 8%, Calquence up 21%, and Farxiga up... 
Via Benzinga
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast. 
Via Benzinga
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech... 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
AstraZeneca’s H1 and Q2 2024 Financial Results
From AstraZeneca
Via Business Wire
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q2 2024
AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints. 
Via Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. 
Via Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
It was another wild week for the market as it had to contend with a lot of news. 
Via Talk Markets
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.